US regulators rejected a skin cancer treatment from Replimune Group Inc. in another sign of the agency’s new leadership ...

Alzheimer’s disease remains one of medicine’s toughest challenges, affecting millions and costing trillions of dollars ...

Scientists at UCSF and Gladstone Institutes have identified cancer drugs that promise to reverse the changes that occur in ...

The Supreme Court’s recent unanimous decision on FDA’s drug-approval authority is utterly unremarkable.

Sarepta Therapeutics is pausing shipments of its gene therapy for muscular dystrophy following several patient deaths that ...

Study harnesses a cell-type-specific, multi-target drug discovery strategy grounded in human data and real-world evidence.

A combination of two cancer drugs may provide a pathway to treat Alzheimer’s, according to a study published July 21 in Cell.  Researchers from the University of California San Francisco developed and ...

George Francis Tidmarsh, MD, PhD, founding co-director of Stanford’s Master of Translational Research and Applied Medicine ...

A Food and Drug Administration expert panel has reignited a debate over whether hormone therapy should be used to treat ...

Study finds two cancer drugs could slow Alzheimer's disease in mice, offering promise for reversing symptoms in humans.

With so few Alzheimer’s drugs available, repurposing medications approved for other conditions could be the key to tackling ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...